Pretransplant Soluble CD30 Is a Better Predictor of Posttransplant Development of Donor-Specific Antibodies and Acute Vascular Rejection than Panel Reactive Antibodies
Authors:
- Smita VaidyaSVSmita Vaidya
- David PartlowDPDavid Partlow
- Titus BarnesTBTitus Barnes
- Kristine GugliuzzaKGKristine Gugliuzza
- 27 December 2006
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 82 (12) , 1606-1609
Abstract
This study tests a hypothesis that pretransplant concentration of soluble CD30 (sCD30) is a better predictor of posttransplant development of donor-specific HLA antibodies (DSA) and acute vascular rejection (AVR) than panel reactive HLA antibodies (PRA).Pretransplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin-inhibitor based immunosuppressive therapy. Objective measurements for rejection were biopsy-proven AVR episodes within first 6 months of the transplant. Posttransplant sera of patients with or without AVR were tested for the presence of DSA.AVR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared to those patients negative for both tests (36% versus 5%, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% versus 5%, p = 0.04). Of the 18 patients with AVR, 14 were positive for sCD30, and 13 of them (93%) developed DSA posttransplant (p = 0.001) Nineteen patients without AVR were tested for DSA and sCD30 concentrations. Only two of these 19 patients were positive for sCD30 and DSA. AVR was strongly associated with the patients tested positive for both the tests: DSA and sCD30 (p = 0.00007). Furthermore, patients with AVR are more likely to produce DSA than those without AVR (p = 0.02).These data support our hypothesis that patients positive for sCD30 contents are at high risk the development of DSA and AVR posttransplant regardless of their pretransplant PRA.Keywords
This publication has 16 references indexed in Scilit:
- Evaluation of Pretransplant Immunologic Status in Kidney-Transplant Recipients by Panel Reactive Antibody and Soluble CD30 DeterminationsTransplantation, 2005
- Pre-Transplant Assessment of Donor-Reactive, HLA-Specific Antibodies in Renal Transplantation: Contraindication vs. RiskAmerican Journal of Transplantation, 2003
- CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 responseTransplant Immunology, 2003
- Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection1Transplantation, 2003
- HLA antibody and donor reactivity define patients at risk for rejection or graft lossHuman Immunology, 2002
- Identification of Highly Responsive Kidney Transplant Recipients Using Pretransplant Soluble CD30Journal of the American Society of Nephrology, 2002
- Kidney graft failure and presensitization against HLA Class I and Class II antigens1Transplantation, 2002
- Flow PRA to detect clinically relevant HLA antibodiesTransplantation Proceedings, 2001
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- CD30-mediated signaling promotes the development of human T helper type 2-like T cells.Journal of Experimental Medicine, 1995